ACORN BIOVENTURES, L.P. - 15 May 2025 Form 4 Insider Report for OnKure Therapeutics, Inc. (OKUR)

Reporting relationship: 10%+ Owner
Issuer ticker: OKUR
Reported as of: 15 May 2025
Net transaction value: +$2,590,000
SEC form: 4
Accepted by SEC: 19 May 2025, 16:43:34 UTC
Prior SEC filing: 09 Oct 2024
Source filing: View source filing
Reporting owner signature: ACORN BIOVENTURES, L.P., By: Acorn Capital Advisors GP, LLC, its general partner, By: /s/ Anders Hove, Manager

Key filing fact

ACORN BIOVENTURES, L.P. filed Form 4 for OnKure Therapeutics, Inc. (OKUR) on 19 May 2025.

Key facts

This page summarizes ACORN BIOVENTURES, L.P.'s Form 4 filing for OnKure Therapeutics, Inc. (OKUR).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2025, 16:43.

Change

Previous filing in this sequence was filed on 09 Oct 2024.
Current net transaction value: +$2,590,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001766853 Primary reporting owner

ACORN BIOVENTURES, L.P.

Relationship: 10%+ Owner
Address: 420 LEXINGTON AVE., SUITE 2626, NEW YORK
Signature: ACORN BIOVENTURES, L.P., By: Acorn Capital Advisors GP, LLC, its general partner, By: /s/ Anders Hove, Manager
Signature date: 19 May 2025

CIK 0001813692

ACORN CAPITAL ADVISORS GP, LLC

Relationship: 10%+ Owner
Address: 420 LEXINGTON AVE., SUITE 2626, NEW YORK
Signature: ACORN CAPITAL ADVISORS GP, LLC, By: /s/ Anders Hove, Manager
Signature date: 19 May 2025

CIK 0001365618

Hove Anders D

Relationship: 10%+ Owner
Address: 420 LEXINGTON AVE., SUITE 2626, NEW YORK
Signature: /s/ Anders Hove
Signature date: 19 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OKUR transaction

Common Stock

Purchase

Transaction value: $500,000
Shares: +270,270
Change %: +19%
Price: $1.85
Shares after: 1,709,944
Date: 15 May 2025
Ownership: Direct
Footnotes: F1

OKUR transaction

Common Stock

Purchase

Transaction value: $2,090,000
Shares: +1,129,730
Change %
Price: $1.85
Shares after: 1,129,730
Date: 15 May 2025
Ownership: By Acorn Bioventures 2, L.P.
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares held directly by Acorn Bioventures, L.P. ("Acorn"). Acorn Capital Advisors GP, LLC ("Acorn GP") is the general partner of Acorn. Anders Hove is the manager of Acorn GP. Each of Acorn GP and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F2

Shares held directly by Acorn Bioventures 2, L.P. ("Acorn 2"). Acorn Capital Advisors GP 2, LLC ("Acorn GP 2") is the general partner of Acorn 2. Anders Hove is the manager of Acorn GP 2. Each of Acorn GP 2 and Mr. Hove disclaims beneficial ownership of disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.